| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa1124b78edc5b18d3be4ac94e06a7be |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C279-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C323-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-55 |
| filingDate |
2017-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ac546a00deae67f085c2d53e2e34bb6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdfd52593e42f9b6556b391181e76271 |
| publicationDate |
2020-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020023067-A1 |
| titleOfInvention |
Dual-action elafibranor metformin salt for treating obesity associated with non-alcoholic steatohepatitis (nash) and hypertriglyceridaemia |
| abstract |
Drugs derived from elafibranor. One or more embodiments relate more particularly to a composition comprising at least one active principle, wherein the at least one active principle comprises an elafibranor metformin salt. One or more embodiments also relate to a derivative of elafibranor having dual action for treating obesity associated with non-alcoholic steatohepatitis (NASH) and hypertriglyceridaemia. |
| priorityDate |
2016-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |